Neuren Pharmaceuticals Ltd (NEU) - Total Liabilities
Based on the latest financial reports, Neuren Pharmaceuticals Ltd (NEU) has total liabilities worth AU$7.98 Million AUD (≈ $5.64 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore NEU cash flow metrics to assess how effectively this company generates cash.
Neuren Pharmaceuticals Ltd - Total Liabilities Trend (2000–2024)
This chart illustrates how Neuren Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Neuren Pharmaceuticals Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Neuren Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Neuren Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fujian Longxi Bearing Group Co Ltd
SHG:600592
|
China | CN¥850.66 Million |
|
Wavestone S.A.
PA:WAVE
|
France | €289.06 Million |
|
Hubei Tech Semiconductors Co
SHE:300046
|
China | CN¥106.72 Million |
|
Wah Lee Industrial Corp
TW:3010
|
Taiwan | NT$30.84 Billion |
|
Fujian Boss Software Development Co Ltd
SHE:300525
|
China | CN¥1.29 Billion |
|
Chengdu Zhimingda Electronics Co. Ltd. A
SHG:688636
|
China | CN¥652.94 Million |
|
Jiangxi Firstar Panel Technology Co Ltd
SHE:300256
|
China | CN¥835.55 Million |
|
BIRLASOFT LIMITED
NSE:BSOFT
|
India | Rs11.30 Billion |
Liability Composition Analysis (2000–2024)
This chart breaks down Neuren Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Neuren Pharmaceuticals Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 40.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.75 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neuren Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neuren Pharmaceuticals Ltd (2000–2024)
The table below shows the annual total liabilities of Neuren Pharmaceuticals Ltd from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | AU$45.80 Million ≈ $32.41 Million |
+7.11% |
| 2023-12-31 | AU$42.76 Million ≈ $30.26 Million |
+2448.45% |
| 2022-12-31 | AU$1.68 Million ≈ $1.19 Million |
+108.97% |
| 2021-12-31 | AU$803.00K ≈ $568.17K |
+6.64% |
| 2020-12-31 | AU$753.00K ≈ $532.80K |
+34.70% |
| 2019-12-31 | AU$559.00K ≈ $395.53K |
-71.67% |
| 2018-12-31 | AU$1.97 Million ≈ $1.40 Million |
+24.87% |
| 2017-12-31 | AU$1.58 Million ≈ $1.12 Million |
-22.05% |
| 2016-12-31 | AU$2.03 Million ≈ $1.43 Million |
-18.98% |
| 2015-12-31 | AU$2.50 Million ≈ $1.77 Million |
-17.37% |
| 2014-12-31 | AU$3.03 Million ≈ $2.14 Million |
+47.13% |
| 2013-12-31 | AU$2.06 Million ≈ $1.46 Million |
-3.89% |
| 2012-12-31 | AU$2.14 Million ≈ $1.52 Million |
+27.20% |
| 2011-12-31 | AU$1.68 Million ≈ $1.19 Million |
-22.90% |
| 2010-12-31 | AU$2.18 Million ≈ $1.55 Million |
-25.64% |
| 2009-12-31 | AU$2.94 Million ≈ $2.08 Million |
-1.19% |
| 2008-12-31 | AU$2.97 Million ≈ $2.10 Million |
-57.76% |
| 2007-12-31 | AU$7.04 Million ≈ $4.98 Million |
+108.31% |
| 2006-12-31 | AU$3.38 Million ≈ $2.39 Million |
+10.88% |
| 2005-12-31 | AU$3.05 Million ≈ $2.16 Million |
-27.41% |
| 2004-12-31 | AU$4.20 Million ≈ $2.97 Million |
-72.78% |
| 2003-12-31 | AU$15.41 Million ≈ $10.91 Million |
+921.40% |
| 2002-12-31 | AU$1.51 Million ≈ $1.07 Million |
-91.01% |
| 2001-12-31 | AU$16.78 Million ≈ $11.87 Million |
+120.34% |
| 2000-12-31 | AU$7.62 Million ≈ $5.39 Million |
-- |
About Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 cl… Read more